MedicarePartD.guide

A non-government resource built from CMS public data

JAK inhibitors and other oral immunology drugs on SilverScript Choice (S5601-066)

Rinvoq, Xeljanz, Olumiant and Otezla, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), Hawaii
Premium
$14.70/month
Deductible
$615.00
Change plan

3 of 5 JAK inhibitors are covered on this plan. All 3 require prior authorization.

2 aren't on the formulary (Olumiant and Otezla).

  • Rinvoq
    upadacitinib
    Covered · prior auth
    from $1,627.94
    Tier 5
  • Xeljanz
    tofacitinib
    Covered · prior auth
    from $1,120.49
    Tier 5
  • Sotyktu
    deucravacitinib
    Covered · prior auth
    $1,755.35
    Tier 5
Not on the formulary
Olumiant, Otezla

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list